Clinical trials: Cardiovascular Events
Atherosclerotic Cardiovascular Disease
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
Primary Objective: To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and…
- Trial name
- NCT01663402
- Testing
- Alirocumab, LMT
- Where
- 1,388 sites in United States, Argentina and 55 more
- Volunteers
- 18,924 people
- Sponsor
- Sanofi
Chest Wall Tumor, Breast Cancer
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Radiation therapy is an essential treatment for tumors in the chest area, including breast, lung, esophageal, mediastinal cancers, and spine metastases.
- Conditions
- Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- NCT07685938
- Testing
- Atorvastatin and Lisinopril
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Stroke, Ischemic, Cardiovascular Risk Factor
Development of a Prognostic Tool for the Stratification of Cardiovascular Risk in Patients With Ischemic Stroke
The availability of several high-cost strategies for the prevention of cardiovascular morbidity and mortality in patients with established cardiovascular disease highlights the necessity of reliable risk stratification of these…
- Conditions
- Stroke, Ischemic, Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Morbidity
- Trial name
- NCT04189497
- Where
- Greece
- Volunteers
- 3,500 people
- Sponsor
- University of Thessaly
Myocardial Infarction
Effects of Early Statin Treatment After Acute Myocardial Infarction (AMI) in Japanese Patients
Statins have been shown to prevent coronary artery disease and to preserve left ventricular function in dilated cardiomyopathy. The investigators hypothesized that the early use of statins would reduce cardiovascular events…
- Trial name
- NCT00128024
- Testing
- lipid-lowering treatment
- Where
- Japan
- Volunteers
- 460 people
- Sponsor
- Kumamoto University
Cardiac Disease, Cancer
Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)
Antineoplastic and immunomodulating agents may lead to various cardio-vascular adverse reactions. This study investigates reports of cardio-vascular toxicities for treatment including Anatomical Therapeutic Chemical (ATC)…
- Trial name
- EROCA (NCT03530215)
- Testing
- Antineoplastic and Immunomodulating Agents
- Where
- France
- Volunteers
- 500,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Preoperative Care, Surgery--Complications
Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study
The proportion of noncardiac surgeries performed as same-day surgery is increasing worldwide, with more complex surgeries being performed on higher risk patients in the outpatient setting.
- Conditions
- Preoperative Care, Surgery--Complications, Myocardial Infarction
- Trial name
- VALIANCE (NCT04973397)
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Cardiovascular Disease
PeriOperative ISchemic Evaluation-2 Trial
Major surgeries not involving the heart are common, and major heart problems during or after such surgeries represent a large population health problem.
- Trial name
- POISE-2 (NCT01082874)
- Testing
- Active Clonidine, Active ASA
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 10,010 people
- Sponsor
- Hamilton Health Sciences Corporation
Heart Failure
Telemonitoring and Teleintervention of Heart Failure and Decrease of Non-fatal Events.
The primary objective of the study is to determine the effect of automated daily selfreported symptom and weight, blood pressure and heart rate monitoring and clinical follow-up videoconference comigrate with clinical follow-up…
- Trial name
- ICOR (NCT01495078)
- Testing
- Telemonitoring
- Where
- Spain
- Volunteers
- 178 people
- Sponsor
- Parc de Salut Mar
Peripheral Arterial Occlusive Disease
Troponin T as Risk Stratification Tool in Peripheral Arterial Occlusive Disease
Study hypothesis: elevated Troponin T is a marker of increased mortality in patients with peripheral arterial occlusive disease (PAOD).
- Trial name
- NCT01087385
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- University Heart Center Freiburg - Bad Krozingen
Atrial Fibrillation, Stroke, Acute
Characterization and Prediction of Atrial Fibrillation-caused Adverse Events After Hospital Discharge for Cardiac Surgery
The purpose of the research is to identify the frequency and severity of adverse events related to atrial fibrillation that occur after discharge from hospital where the patient underwent cardiac surgery.
- Conditions
- Atrial Fibrillation, Stroke, Acute, Death
- Trial name
- MATRICeS (NCT03466125)
- Testing
- Cardiac surgery
- Where
- United States
- Volunteers
- 25,000 people
- Sponsor
- Brigham and Women's Hospital
Parkinson's Disease, Hyperprolactinemia
The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
To assess the association between cabergoline and other dopamine agonists (DAs), and symptomatic, diagnosed serious cardiopulmonary disorders, including: 1. Cardiac valve regurgitation 2.
- Trial name
- NCT01052948
- Testing
- Retrospective study-
- Volunteers
- 86,939 people
- Sponsor
- Pfizer
Diabetes Mellitus, Heart Failure
Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients
Increased levels of NT-proBNP are known to increase the risk of cardiac events in diabetic patients. The other way around, patients with normal values have an excellent prognosis on short-term.
- Conditions
- Diabetes Mellitus, Heart Failure, Coronary Artery Disease
- Trial name
- PONTIAC (NCT00562952)
- Testing
- Telmisartan, Bisoprolol
- Where
- 2 sites in Austria
- Volunteers
- 300 people
- Sponsor
- Medical University of Vienna
Cardiovascular Disease
Role of Vitamin D in Secondary Prevention of Cardiovascular Events
The purpose of this study is to determine if Vitamin D supplementation helps prevent recurrent cardiovascular events, such as heart attack or stroke, in patients who have already experienced at least one cardiovascular event.
- Trial name
- NCT01018849
- Testing
- Cholecalciferol
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Creighton University
Hypertension, Type 2 Diabetes Mellitus
Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
Various guidelines recommended angiotensin converting enzyme (ACE) inhibitors or angiotensin Ⅱ receptor-1 blockers (ARBs) for hypertensive patients with diabetes on the basis of the cardiac- and reno-protective effects of these…
- Trial name
- NCT00129233
- Testing
- Valsartan, Amlodipine
- Where
- Japan
- Volunteers
- 1,150 people
- Sponsor
- Nagoya University
Cardiovascular Risk Assessment
Prognosis of Type 2 Diabetic Patients
The study will include 1200 patients with type 2 diabetes and angiographically documented coronary artery disease and 600 matched non-diabetic patients without type 2 diabetes.
- Trial name
- ARTEMIS (NCT01426685)
- Where
- Finland
- Volunteers
- 1,880 people
- Sponsor
- University of Oulu
Non-Small Cell Lung Carcinoma, Venous Thromboembolism
Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma
The association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis.
- Trial name
- NCT00192829
- Testing
- Blood sample withdrawal
- Where
- 2 sites in Israel
- Volunteers
- 100 people
- Sponsor
- Rambam Health Care Campus
Coronary Artery Disease, DES
A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial
We hypothesized that clopidogrel mono-therapy will not be inferior to the extended DAPT in terms of the occurrence of both ischemic and bleeding events, for lesions or patients at high risk for either ischemic or bleeding…
- Trial name
- NCT03947229
- Testing
- Clopidogrel mono-therapy, Dual-antiplatelet therapy
- Where
- South Korea
- Volunteers
- 3,200 people
- Sponsor
- Yonsei University
Post-immunisation Apnoea and Bradycardia of Prematurity (AOP)
Predictive Value of Heart Rate Variability on Cardiorespiratory Events
The aim of this study are to investigate whether heart rate variability (HRV) parameters derived from nonlinear time series analysis at five different time points have prognostic utility for assessing the risk of postimmunisation…
- Trial name
- NCT04303494
- Testing
- immunisation
- Where
- Switzerland
- Volunteers
- 292 people
- Sponsor
- University Hospital, Basel, Switzerland
Diabetic Retinopathy
Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy
To assess whether neuroprotective drugs administered topically (somatostatin and brimonidine) are able to prevent or arrest the development and progression of neurodegenerative changes
- Trial name
- EUROCONDOR (NCT01726075)
- Testing
- COLIRIOBCN070660, Brimonidine
- Where
- 11 sites in Denmark, France and 5 more
- Volunteers
- 450 people
- Sponsor
- BCN Peptides
Atrial Fibrillation, Tachycardia
Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems
This is an observational registry study aiming to collect data on efficacy and safety of the single chamber Biotronik DX system with enhanced atrial diagnostics. The minimal follow-up period is 24 months.
- Conditions
- Atrial Fibrillation, Tachycardia, ICD Therapy, Thromboembolic Events
- Trial name
- MATRIX (NCT01774357)
- Where
- Germany
- Volunteers
- 2,054 people
- Sponsor
- Biotronik SE & Co. KG